يعرض 1 - 14 نتائج من 14 نتيجة بحث عن '"Gooden, K.M."', وقت الاستعلام: 0.40s تنقيح النتائج
  1. 1
    Academic Journal
    Treatment-free survival, with and without toxicity, as a novel outcome applied to immuno-oncology agents in advanced renal cell carcinoma

    المؤلفون: Regan, M.M., Atkins, M.B., Powles, T., Werner, L., Mantia, C., Yang, S., Johansen, J.L., Rao, S., Gooden, K.M., McDermott, D.F.

    المصدر: Annals of Oncology ; volume 30, page v393-v394 ; ISSN 0923-7534

    الاتاحة: http://dx.doi.org/10.1093/annonc/mdz249.067
    https://api.elsevier.com/content/article/PII:S0923753419591840?httpAccept=text/xml
    https://api.elsevier.com/content/article/PII:S0923753419591840?httpAccept=text/plain
    http://academic.oup.com/annonc/article-pdf/30/Supplement_5/mdz249.067/30083328/mdz249.067.pdf

    View record in BASE

    أضف إلى المفضلة
  2. 2
    Academic Journal
    PCN264 QUALITY ADJUSTED TIME WITHOUT SYMPTOMS OF DISEASE PROGRESSION OR TOXICITY (Q-TWIST) OF NIVOLUMAB PLUS IPILIMUMAB (NIVO+IPI) VS SUNITINIB (SUN) AMONG UNTREATED ADVANCED RENAL CELL CARCINOMA (ARCC) PATIENTS (PATIENTS) WITH INTERMEDIATE OR POOR PROGNOSTIC RISK

    المؤلفون: Shah, R., Botteman, M., Kwon, Y., Gooden, K.M., Cella, D., Motzer, R.

    المصدر: Value in Health ; volume 22, page S106 ; ISSN 1098-3015

    الاتاحة: http://dx.doi.org/10.1016/j.jval.2019.04.385
    https://api.elsevier.com/content/article/PII:S1098301519305777?httpAccept=text/xml
    https://api.elsevier.com/content/article/PII:S1098301519305777?httpAccept=text/plain

    View record in BASE

    أضف إلى المفضلة
  3. 3
    Academic Journal
    PCN127 COST-EFFECTIVENESS ANALYSIS OF NIVOLUMAB IN COMBINATION WITH IPILIMUMAB COMPARED WITH CURRENTLY AVAILABLE FIRST-LINE TREATMENTS IN PATIENTS WITH PREVIOUSLY UNTREATED METASTATIC RENAL CELL CARCINOMA IN THE UNITED STATES

    المؤلفون: Tanova, N., Yang, S., Cheung, L.H., Genestier, V., Gooden, K.M., Malcolm, B., Rao, S., Choueiri, T.K.

    المصدر: Value in Health ; volume 22, page S80 ; ISSN 1098-3015

    الاتاحة: http://dx.doi.org/10.1016/j.jval.2019.04.251
    https://api.elsevier.com/content/article/PII:S1098301519304437?httpAccept=text/xml
    https://api.elsevier.com/content/article/PII:S1098301519304437?httpAccept=text/plain

    View record in BASE

    أضف إلى المفضلة
  4. 4
    Academic Journal
    PCN240 EVALUATING PARTITIONED SURVIVAL MODEL AND RESPONSE-BASED MODELING APPROACHES FOR USE IN COST-EFFECTIVENESS ANALYSIS: ESTIMATING AND VALIDATING SURVIVAL OUTCOMES

    المؤلفون: Lakhdari, K., Young, K.C., Berling, M., Gooden, K.M., Holdgate, O.

    المصدر: Value in Health ; volume 22, page S101-S102 ; ISSN 1098-3015

    الاتاحة: http://dx.doi.org/10.1016/j.jval.2019.04.361
    https://api.elsevier.com/content/article/PII:S1098301519305534?httpAccept=text/xml
    https://api.elsevier.com/content/article/PII:S1098301519305534?httpAccept=text/plain

    View record in BASE

    أضف إلى المفضلة
  5. 5
    Academic Journal
    PCN170 COST-EFFECTIVENESS OF NIVOLUMAB IN COMBINATION WITH IPILIMUMAB COMPARED TO SUNITINIB IN THE FIRST-LINE TREATMENT OF ADVANCED OR METASTATIC INTERMEDIATE- OR POOR-RISK RENAL CELL CARCINOMA IN ITALY

    المؤلفون: Di Rienzo, P., Zarrelli, L., Mennini, F.S., Marcellusi, A., Bini, C., Malcolm, B., May, J., Gooden, K.M., Van de Wetering, G., Smith van Carroll, L.E.

    المصدر: Value in Health ; volume 22, page S469 ; ISSN 1098-3015

    الاتاحة: http://dx.doi.org/10.1016/j.jval.2019.09.366
    https://api.elsevier.com/content/article/PII:S1098301519327445?httpAccept=text/xml
    https://api.elsevier.com/content/article/PII:S1098301519327445?httpAccept=text/plain

    View record in BASE

    أضف إلى المفضلة
  6. 6
    Academic Journal
    PCN143 COMPARISON OF ADVERSE EVENT COSTS OF NIVOLUMAB+IPILIMUMAB VERSUS SUNITINIB FOR PREVIOUSLY UNTREATED INTERMEDIATE-/POOR-RISK ADVANCED RENAL CELL CARCINOMA IN PORTUGAL

    المؤلفون: Alves, D., Polanco Sánchez, C., Gooden, K.M., May, J., Malcolm, B., Du, E.X., Yin, L., Betts, K.A.

    المصدر: Value in Health ; volume 22, page S463 ; ISSN 1098-3015

    الاتاحة: http://dx.doi.org/10.1016/j.jval.2019.09.339
    https://api.elsevier.com/content/article/PII:S1098301519327172?httpAccept=text/xml
    https://api.elsevier.com/content/article/PII:S1098301519327172?httpAccept=text/plain

    View record in BASE

    أضف إلى المفضلة
  7. 7
    Academic Journal
    PCN26 QUANTIFYING THE RELATIVE CLINICAL VALUE OF NIVOLUMAB PLUS IPILIMUMAB VS. SUNITINIB IN FIRST-LINE ADVANCED OR METASTATIC RENAL CELL CARCINOMA WITH THE NUMBER NEEDED TO TREAT AND NUMBER NEEDED TO HARM IN SPAIN AND PORTUGAL

    المؤلفون: Polanco Sánchez, C., Alves, D., Gooden, K.M., May, J., Malcolm, B., Du, E.X., Betts, K.A.

    المصدر: Value in Health ; volume 22, page S440 ; ISSN 1098-3015

    الاتاحة: http://dx.doi.org/10.1016/j.jval.2019.09.223
    https://api.elsevier.com/content/article/PII:S1098301519326014?httpAccept=text/xml
    https://api.elsevier.com/content/article/PII:S1098301519326014?httpAccept=text/plain

    View record in BASE

    أضف إلى المفضلة
  8. 8
    Academic Journal
    PCN146 VALIDATION OF PREDICTED SURVIVAL ESTIMATES FROM PREVIOUS DATA CUTS OF THE PHASE III CHECKMATE 025 STUDY IN ADVANCED RENAL CELL CARCINOMA

    المؤلفون: Kurt, M., May, J., Malcolm, B., Gooden, K.M., Borrill, J., Holdgate, O., Teitsson, S.

    المصدر: Value in Health ; volume 22, page S463-S464 ; ISSN 1098-3015

    الاتاحة: http://dx.doi.org/10.1016/j.jval.2019.09.342
    https://api.elsevier.com/content/article/PII:S1098301519327202?httpAccept=text/xml
    https://api.elsevier.com/content/article/PII:S1098301519327202?httpAccept=text/plain

    View record in BASE

    أضف إلى المفضلة
  9. 9
    Academic Journal
    PCN111 COMPARISON OF ADVERSE EVENT COSTS OF NIVOLUMAB+IPILIMUMAB VERSUS SUNITINIB FOR PREVIOUSLY UNTREATED INTERMEDIATE-/POOR-RISK ADVANCED RENAL CELL CARCINOMA IN SWITZERLAND

    المؤلفون: Oniangue-Ndza, C., Gooden, K.M., May, J., Malcolm, B., Du, E.X., Yin, L., Betts, K.A.

    المصدر: Value in Health ; volume 22, page S457 ; ISSN 1098-3015

    الاتاحة: http://dx.doi.org/10.1016/j.jval.2019.09.308
    https://api.elsevier.com/content/article/PII:S1098301519326865?httpAccept=text/xml
    https://api.elsevier.com/content/article/PII:S1098301519326865?httpAccept=text/plain

    View record in BASE

    أضف إلى المفضلة
  10. 10
    Academic Journal
    PCN421 STABILITY OF LIFETIME OVERALL SURVIVAL ESTIMATES OF NIVOLUMAB+IPILIMUMAB IN FIRST-LINE ADVANCED/METASTATIC INTERMEDIATE- OR POOR-RISK RENAL CELL CARCINOMA

    المؤلفون: Cakar, E., May, J., Malcolm, B., Gooden, K.M., Klijn, S.

    المصدر: Value in Health ; volume 22, page S517-S518 ; ISSN 1098-3015

    الاتاحة: http://dx.doi.org/10.1016/j.jval.2019.09.614
    https://api.elsevier.com/content/article/PII:S1098301519329924?httpAccept=text/xml
    https://api.elsevier.com/content/article/PII:S1098301519329924?httpAccept=text/plain

    View record in BASE

    أضف إلى المفضلة
  11. 11
    Academic Journal
    PCN115 COMPARISON OF ADVERSE EVENT COSTS OF NIVOLUMAB+IPILIMUMAB VERSUS SUNITINIB FOR PREVIOUSLY UNTREATED INTERMEDIATE-/POOR-RISK ADVANCED RENAL CELL CARCINOMA IN SPAIN

    المؤلفون: Polanco Sánchez, C., Gooden, K.M., May, J., Malcolm, B., Du, E.X., Yin, L., Betts, K.

    المصدر: Value in Health ; volume 22, page S458 ; ISSN 1098-3015

    الاتاحة: http://dx.doi.org/10.1016/j.jval.2019.09.312
    https://api.elsevier.com/content/article/PII:S1098301519326907?httpAccept=text/xml
    https://api.elsevier.com/content/article/PII:S1098301519326907?httpAccept=text/plain

    View record in BASE

    أضف إلى المفضلة
  12. 12
    Academic Journal
    PCN140 COST-EFFECTIVENESS OF NIVOLUMAB IN COMBINATION WITH IPILIMUMAB COMPARED TO SUNITINIB FOR THE FIRST-LINE TREATMENT OF ADVANCED/METASTATIC INTERMEDIATE- OR POOR-RISK RENAL CELL CARCINOMA IN SWITZERLAND

    المؤلفون: Oniangue-Ndza, C., Schneider, R., Malcolm, B., May, J., Gooden, K.M., Klijn, S., Cakar, E.

    المصدر: Value in Health ; volume 22, page S462 ; ISSN 1098-3015

    الاتاحة: http://dx.doi.org/10.1016/j.jval.2019.09.336
    https://api.elsevier.com/content/article/PII:S1098301519327147?httpAccept=text/xml
    https://api.elsevier.com/content/article/PII:S1098301519327147?httpAccept=text/plain

    View record in BASE

    أضف إلى المفضلة
  13. 13
    Academic Journal
    PCN157 COST-EFFECTIVENESS ANALYSIS OF NIVOLUMAB + IPILIMUMAB VERSUS SUNITINIB IN THE FIRST-LINE TREATMENT OF ADVANCED OR METASTATIC INTERMEDIATE- OR POOR-RISK RENAL CELL CARCINOMA IN SPAIN

    المؤلفون: Polanco Sánchez, C., Pérez-Alcántara, F., May, J., Gooden, K.M., Malcolm, B., Arranz, J.A., Duran, I., García-Donas, J., Gallardo, E., Láinez, N., Maroto, P., Valderrama, B.P., Puente, J., Vázquez, S., Van de Wetering, G., Smith van Carroll, L.E.

    المصدر: Value in Health ; volume 22, page S466 ; ISSN 1098-3015

    الاتاحة: http://dx.doi.org/10.1016/j.jval.2019.09.353
    https://api.elsevier.com/content/article/PII:S1098301519327317?httpAccept=text/xml
    https://api.elsevier.com/content/article/PII:S1098301519327317?httpAccept=text/plain

    View record in BASE

    أضف إلى المفضلة
  14. 14
    Academic Journal
    PCN23 UPDATED NETWORK META-ANALYSIS OF TREATMENTS IN FIRST-LINE ADVANCED/METASTATIC INTERMEDIATE- OR POOR-RISK RENAL CELL CARCINOMA.

    المؤلفون: Cakar, E.1 (AUTHOR), May, J.2 (AUTHOR), Malcolm, B.3 (AUTHOR), Gooden, K.M.4 (AUTHOR), Klijn, S.1 (AUTHOR)

    المصدر: Value in Health. 2019 Supplement 3, Vol. 22, pS439-S439. 1p.

    مصطلحات موضوعية: *RENAL cell carcinoma, *IPILIMUMAB, *EVEROLIMUS, *META-analysis, *RANDOM effects model

    Full Text Finder

    أضف إلى المفضلة
أدوات البحث: أحصل على تغذية RSS – أرسل هذا البحث بالبريد الإلكتروني – حفظ البحث – جدول التنبيهات: لا شيء